Abeona Therapeutics Inc

Home
United States
Manhattan, NY
Abeona Therapeutics Inc

Directions Website

Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated cell and gene therapy company. Abeona Therapeutics Inc.

(Nasdaq: ABEO) is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases

Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases.

10/30/2026

Sometimes the most meaningful awareness begins with simply understanding someone's experience.

As we close out EB Awareness Week, Sarah shares an important reminder: EB is more than a skin condition. For many individuals, its impact reaches far beyond what is visible, affecting relationships, daily routines and countless aspects of everyday life.

10/28/2026

Progress is powered by the people behind it.

During , we’re sharing reflections from patients, caregivers and advocates whose experiences highlight the strength, perseverance and hope found throughout the epidermolysis bullosa (EB) community.

Every story is different, but together these voices remind us of the power of connection, the importance of community and the progress that continues to inspire what’s possible. 💙

10/27/2026

Understanding starts with asking questions.

One common misconception about epidermolysis bullosa (EB) is that it is contagious. EB is a rare genetic condition that individuals are born with. As Armando shares, increasing understanding starts with asking questions, listening and learning more about the experiences of those living with EB.

10/25/2026

Every epidermolysis bullosa (EB) story is unique.

During EB Awareness Week, we’re sharing perspectives from members of the EB community to help raise awareness, deepen understanding and shine a light on the realities of living with EB.

Thank you to the patients, caregivers and advocates who continue to share their experiences and help educate others.

10/05/2026

We’re proud to accept the PM360 Magazine Trailblazer Award in the Most Innovative New Product category for our FDA-approved gene therapy for the recessive dystrophic epidermolysis bullosa ( ) community.

This recognition reflects the dedication of the entire Abeona team, but most importantly, it would not be possible without the patients, caregivers, advocates and healthcare professionals who continue to inspire our mission every day.

Thank you for sharing your experiences, raising awareness and helping drive progress for the RDEB community. We are honored to be part of this journey. 💙

09/16/2026

Access to specialized care is an important part of the treatment journey for individuals living with recessive dystrophic epidermolysis bullosa (RDEB).

Abeona announces the activation of the newest Qualified Treatment Center for the administration of our autologous cell-based gene therapy.

Read more: https://bit.ly/4Aido84

08/27/2026

Together with patients, families, caregivers and advocates, Abeona team members participated in DASH4DEBRA in support of the epidermolysis bullosa (EB) community.

Thank you to debra of America for bringing people together to raise awareness and support for those affected by EB.

07/30/2026

We were thrilled to be on site at the 2026 debra of America Care Conference in Los Angeles!

This incredible gathering brought together individuals and families living with epidermolysis bullosa (EB) alongside clinicians and researchers, all united in advancing care, support and innovation for the EB community.

06/19/2026

Caring for someone with an ultra-rare condition like recessive dystrophic epidermolysis bullosa ( ) comes with daily challenges. In this BioSpace Denatured episode, Abeona CEO & Director Vishwas Seshadri shares how new gene and cell therapies could help change what’s possible for patients and families.

Listen here:

In this episode of Denatured, you’ll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We explore how recessive dystrophic epidermolysis bullosa has become a defining case study for gene and cell therapy and what this ultra‑ra...

04/17/2026

We were so excited to jump back in and Plunge for Elodie this year! On April 8, our Cleveland team hosted a dunk tank to support EB Research Partnership and the amazing epidermolysis bullosa (EB) community.

Address

1330 6th Avenue
Manhattan, NY
10019

Website

http://www.abeonatherapeutics.com/

Alerts

Be the first to know and let us send you an email when Abeona Therapeutics Inc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.